If you have been reading about lyophilization and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-08-06. Numbers and descriptions here follow the published literature rather than marketing material.
Reported pharmacological effects center on reduced anxiety-like behavior in animal models and on measures of memory and learning. Proposed contributing mechanisms include modulation of GABAergic signaling, shifts in monoamine turnover, and changes in the activity of enzymes that degrade neuropeptides. Effects on the expression of genes linked to neuroplasticity have also been described. No single molecular target is widely accepted, and whether the behavioral findings arise from one pathway or several remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Regulatory treatment varies by jurisdiction. In Russia the compound is a registered prescription product, while in the European Union and the United States it is generally handled as a research chemical without a marketing authorization. Suppliers therefore operate outside pharmaceutical oversight, and buyers rely on supplier documentation for purity and identity claims. Chain of custody and third-party testing are the main verification tools. Analysts note that the absence of a pharmacopoeial monograph for research-grade material limits standardization across vendors.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C33H57N11O9 | Derived from the seven-residue sequence |
| Molecular weight | About 751.9 g/mol | Average mass; the monoisotopic value is slightly lower |
| Residue count | Seven amino acids | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Parent compound | Tuftsin (Thr-Lys-Pro-Arg) | Selank extends tuftsin at the C-terminus |
| Compound class | Synthetic short peptide | Studied in a research setting; not a licensed drug in most markets |
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
== History == The concept of fatty acid (acide gras) was introduced in 1813 by Michel Eugène Chevreul, though he initially used some variant terms: graisse acide and acide huileux ("acid fat" and "oily acid").
The American Institute for Cancer Research (AICR) and World Cancer Research Fund International (WCRF) have stated that there is strong evidence that consuming salted foods including salt-preserved fish and salt-preserved foods in general increases risk of stomach cancer and that the high salt content of processed meat may result in damage to the stomach mucosal lining. The American Cancer Society have stated that "stomach cancer risk is increased in people whose diets include large amounts of foods preserved by salting, such as salted fish and meat and pickled vegetables." Additionally, an excessive intake of salt has a dose-response relationship with elevated blood pressure, increasing the risk of several cardiovascular diseases.
== Wallerian degeneration slow == Mice belonging to the strain C57BL/Wlds have delayed Wallerian degeneration, and, thus, allow for the study of the roles of various cell types and the underlying cellular and molecular processes. Current understanding of the process has been possible via experimentation on the Wlds strain of mice. The mutation occurred first in mice in Harlan-Olac, a laboratory producing animals the United Kingdom. The Wlds mutation is an autosomal-dominant mutation occurring in the mouse chromosome 4. The gene mutation is an 85-kb tandem triplication, occurring naturally. The mutated region contains two associated genes: nicotinamide mononucleotide adenylyltransferase 1 (NMNAT1) and ubiquitination factor e4b (UBE4B). A linker region encoding 18 amino acids is also part of the mutation. The protective effect of the WldS protein has been shown to be due to the NMNAT1 region's NAD+ synthesizing active site. Although the protein created localizes within the nucleus and is barely detectable in axons, studies suggest that its protective effect is due to its presence in axonal and terminal compartments. The protection provided by the WldS protein is intrinsic to the neurons and not surrounding support cells, and is only locally protective of the axon, indicating an intracellular pathway is responsible for mediating Wallerian degeneration.
However, proactively smiling only increases happiness among those who believe smiling is a reaction to feeling happy, rather than a positive intervention. Ed Diener et al. (1999) suggested this equation: positive emotion – negative emotion = subjective well-being. Since tendency to positive emotion has a correlation of 0.8 with extroversion and tendency towards negative emotion is indistinguishable from neuroticism, the above equation could also be written as extroversion – neuroticism = happiness. These two traits could account for between 50% and 75% of happiness. These are all referring to the Big Five personality traits model of personality. An emotionally stable (the opposite of Neurotic) personality correlates well with happiness. Not only does emotional stability make one less prone to negative emotions, it also predicts higher social intelligence – which helps to manage relationships with others (an important part of being happy, discussed below). Cultivating an extroverted temperament may correlate with happiness for the same reason: it builds relationships and support groups. Some people may be fortunate, from the standpoint of personality theories that suggest individuals have control over their long-term behaviors and cognitions. Genetic studies indicate genes for personality (specifically extroversion, neuroticism and conscientiousness), and a general factor linking all 5 traits, account for the heritability of subjective well-being. Recent research suggests there is a happiness gene, the 5-HTT gene.
Sources: en.wikipedia.org
=== Early DNA sequencing methods === The first method for determining DNA sequences involved a location-specific primer extension strategy established by Ray Wu, a Chinese-born American geneticist, at Cornell University in 1970. DNA polymerase catalysis and specific nucleotide labeling, both of which figure prominently in current sequencing schemes, were used to sequence the cohesive ends of lambda phage DNA. Between 1970 and 1973, Wu, scientist Radha Padmanabhan, and colleagues demonstrated that this method can be employed to determine any DNA sequence using synthetic location-specific primers. Walter Gilbert, a biochemist, and Allan Maxam, a molecular geneticist, at Harvard also developed sequencing methods, including one for "DNA sequencing by chemical degradation". In 1973, Gilbert and Maxam reported the sequence of 24 basepairs using a method known as wandering-spot analysis. Advancements in sequencing were aided by the concurrent development of recombinant DNA technology, allowing DNA samples to be isolated from sources other than viruses. Two years later in 1975, Frederick Sanger, a biochemist, and Alan Coulson, a genome scientist, developed a method to sequence DNA. The technique known as the "Plus and Minus" method, involved supplying all the components of the DNA but excluding the reaction of one of the four bases needed to complete the DNA. In 1976, Gilbert and Maxam, invented a method for rapidly sequencing DNA while at Harvard, known as the Maxam–Gilbert sequencing.
=== Brand names === GABOB is sold primarily under the brand name Gamibetal. It has also been marketed under a variety of other brand names including Aminoxan, Bogil, Diastal, Gabimex, Gabomade, Gaboril, Gamalate, and Kolpo.
Serotonin 5-HT2A receptor antagonists can block the subjective psychedelic effects of serotonergic psychedelics in humans. Numerous drugs act as serotonin 5-HT2A receptor antagonists, for instance antidepressants like trazodone and mirtazapine, antipsychotics like quetiapine, olanzapine, and risperidone, and other agents like ketanserin, pimavanserin, cyproheptadine, and pizotifen. Such drugs are sometimes referred to as "trip killers" due to their ability to prevent or abort the hallucinogenic effects of psychedelics. Serotonin 5-HT2A receptor antagonists like antipsychotics should be stopped 5 half-lives or at least 7 days prior to a psychedelic session. Besides serotonin 5-HT2A receptor antagonists, non-hallucinogenic serotonin 5-HT2A receptor partial agonists, such as lisuride, may also block the hallucinogenic effects of serotonergic psychedelics. Dopamine D2 receptor antagonists such as the typical antipsychotic haloperidol can cause anxiety and dysphoria when combined with psychedelic drugs. The same may be true of other dopamine D2 receptor antagonists such as metoclopramide. Unlike atypical antipsychotics, which also have concomitant serotonin 5-HT2A receptor antagonism, more selective dopamine D2 receptor antagonists like haloperidol do not block the hallucinogenic effects of psychedelics and hence are not useful as "trip killers". Due to the increased risk of negative experiences, it is recommended that dopamine D2 receptor antagonists like haloperidol and metoclopramide not be combined with psychedelics.
Limulus amebocyte lysate (LAL) is an aqueous extract of motile blood cells (amebocytes) from the Atlantic horseshoe crab Limulus polyphemus. LAL reacts with bacterial endotoxins such as lipopolysaccharides (LPS), which are components of the bacterial capsule, the outermost membrane of cell envelope of gram-negative bacteria. This reaction is the basis of the LAL test, which is widely used for the detection and quantification of bacterial endotoxins. In Asia, a similar Tachypleus amebocyte lysate (TAL) test based on the local horseshoe crabs Tachypleus gigas or Tachypleus tridentatus is occasionally used instead. The recombinant factor C (rFC) assay is a replacement of LAL and TAL based on a similar reaction.
=== Pregnancy === Before 2015, tazarotene was considered a Category X drug (meaning its use was contraindicated during pregnancy) according to US Food and Drug Administration (FDA) guidelines, despite demonstrating similar plasma retinoid levels as adapalene and tretinoin, which were classified as Category C drugs. Under the FDA's updated Pregnancy and Lactation Labeling Rule which eliminated the lettered pregnancy categories and came into effect in 2015, tazarotene was determined to be contraindicated in pregnancy. Because of the lack of pregnancy outcomes data for the drug, the determination was based on the teratogenic effects observed in rat and rabbit studies.
Sources: en.wikipedia.org
However, Compulsion also said that with this expanded title, the price of the game will be increased from $30 to $60, with those that backed the Kickstarter or purchased the early access versions getting the full game and some of the downloadable content that is planned for free. Compulsion plans to offer a season pass for additional content that will be developed after release, enabled by Gearbox's backing. Compulsion's community manager Nadia Hadjas said that neither Microsoft nor Gearbox provided oversight on the game, allowing Compulsion to develop the title based on their own goals and the community's feedback. In May 2018, the Australian Classification Board had refused classification for We Happy Few, identifying that gameplay mechanics around the use of Joy pills was problematic, which would prevent the game from being sold in Australia. The Board stated in their refusal that because "the game's drug-use mechanic making game progression less difficult constitutes an incentive or reward for drug-use and therefore, the game exceeds the R18+ classification that states, 'drug use related to incentives and rewards is not permitted'". Compulsion Games said that it was working with the Board to challenge their ruling and make the game appropriate to be rated, stating that they believe that the use of Joy was part of the game's themes, "It's a society that is forcing its citizens to take Joy, and the whole point of the game is to reject this programming and fight back", and compared this theme to that of Aldous Huxley's Brave New World and Terry Gilliam's Brazil.
On 21 March 2020, Bukele imposed a 30-day nationwide lockdown in an effort to combat the pandemic. During the lockdown, 4,236 people were arrested by the National Civil Police for violating the lockdown order; 70 were arrested before the lockdown order became public. The arrestees were quarantined in a "containment center". Human rights organizations such as Human Rights Watch criticized the arrests, citing instances of arbitrary arrests and abuse by police. Amid April 2020 lockdowns in the country's prisons and published images of prisoners lined up in cramped positions, Human Rights Watch called the prisons' living conditions "inhumane" (particularly in light of the pandemic). On 27 May 2020, the United States donated 250 ventilators to El Salvador. During a press conference where Bukele received the ventilators, he said that he took hydroxychloroquine as prophylaxis and added that "most of the world's leaders use [hydroxychloroquine] as a prophylaxis". Bukele inaugurated the Hospital El Salvador, the largest hospital in Latin America used exclusively for treating cases of COVID-19 at the site of the former International Center for Fairs and Conventions, on 22 June 2020. The hospital had a capacity of 400 beds, 105 intensive-care units, and 295 intermediate-care units staffed by 240 doctors. In August 2020, the hospital's capacity was increased by 575 beds. It began treating conditions other than COVID-19 by June 2022.
=== Borealis === Shortly before his departure from Valve in 2016, Laidlaw led a virtual reality (VR) project on the Source 2 engine, Borealis, set on the time-travelling ship mentioned in Episode Two and Portal 2. The game would skip between the Combine's conquering of Earth before Half-Life 2 and a time set shortly after Episode Two. A minigame in which players would fish off the bow of the ship was also proposed. Laidlaw said the project ended because it was too early to be working in VR: "When people are struggling with the basic tools they need to rough out a concept, it's hard to convey any sort of vision, and it all evaporated pretty quickly."
Many local effects can influence ice δD in addition to temperature. These effects include moisture origin and transport pathways, evaporation conditions and precipitation seasonality, which can be accounted for in more complicated models. Nevertheless, the Vostok ice core record shows some very important results: (1) A consistent δD depletion of ~70‰ during the last four glacial periods compared to interglacial times, corresponding to a cooling of 8°C in Antarctica; (2) A consistent drop of atmospheric CO2 concentration by 100 ppmv and CH4 drop by ~300 ppbv during glacial times relative to interglacials, suggesting a role of greenhouse gases in regulating global climate; (3) Antarctic air temperature and greenhouse gas concentration changes precede global ice volume and Greenland air temperature changes during glacial terminations, and greenhouse gases may be an amplifier of insolation forcing during glacial-interglacial cycles. Greenland ice core isotope records, in addition to showing glacial-interglacial cycles, also shows millennial-scale climate oscillations that may reflect reorganization in ocean circulation caused by ice melt charges. There have also been ice core records generated in alpine glacials on different continents. A record from the Andes Mountains in Peru shows a temperature decrease of 5-6°C in the tropics during the last ice age. A record from the Tibetan plateau shows a similar isotope shift and cooling during the last ice age.
The role of gastric acid in digestion was established in the 1820s and 1830s by William Beaumont on Alexis St. Martin, who, as a result of an accident, had a fistula (hole) in his stomach, which allowed Beaumont to observe the process of digestion and to extract gastric acid, verifying that acid played a crucial role in digestion.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, designed as a metabolically stabilized analogue of the endogenous tetrapeptide tuftsin. It has been studied mainly against anxiety-related and cognitive endpoints rather than as an approved medicine in most jurisdictions.
Tuftsin contains four residues, while selank carries an additional Pro-Gly-Pro segment at the carboxyl end. That extension is intended to reduce enzymatic cleavage. Comparative pharmacokinetic data in humans remain limited.
No single receptor target is widely accepted as the definitive mediator of the reported effects. Proposed contributors include GABAergic modulation, shifts in monoamine turnover, and altered neuropeptide degradation. The mechanism is treated in the literature as unresolved.
Purity is usually reported as an HPLC area percentage, most often measured at 214 nm. Identity is confirmed separately by mass spectrometry. A certificate of analysis should state both the method and the observed value.